Review Article

Comprehensive Review of Integration of Artificial Intelligence in Pharmacogenomics for Personalized Medicine

Sonali.T.Kolekar*, Omkar.A.Devade, Prakash.D.Jadhav, Neha.S.Pawar, Gaurav.S.Potdar Nikita.C.Mohite, Rahim.M.Shaikh, Chaitali.S.Dalavi, Vaishnavi.V.Bhosale,

Yashoda Technical campus, College of Pharmacy, Satara, Dist- Satara Maharashtra, India.

***Corresponding author's E-mail:** sonalitk123@gmail.com

Received: 11-03-2026; **Revised:** 26-05-2026; **Accepted:** 30-05-2026; **Published online:** 20-06-2026.

ABSTRACT

The convergence of artificial intelligence (AI) and pharmacogenomics represents a transformative paradigm in contemporary medicine. Pharmacogenomics investigates the relationship between individual genetic variations and drug response, whereas AI provides computational frameworks capable of discerning complex patterns within high-dimensional biological datasets. This review comprehensively examines the integration of AI methodologies including machine learning, deep learning, and natural language processing into pharmacogenomic research and clinical practice, with an emphasis on personalized medicine. The applications of AI span the entire continuum of drug development: from target identification and compound discovery to preclinical prediction, clinical trial optimization, real-world data mining, pharmacokinetic modelling, and pharmacogenomics-driven dose individualization. Multi-modal data integration platforms that combine clinical, laboratory, imaging, -omics, wearable device, and environmental data are discussed as essential infrastructure supporting AI-driven decisions. Furthermore, the role of AI in next-generation sequencing (NGS) interpretation, gene functionality scoring, and therapeutic area-specific genetic guidance is elaborated. While promising, the implementation of AI in pharmacogenomics is accompanied by substantial challenges relating to data quality, algorithmic bias, regulatory compliance, and ethical considerations. The review also presents a future outlook wherein AI and precision medicine collaboratively enhance individualized healthcare across clinical, social, and genomic dimensions. A structured synthesis of 55 peer-reviewed references is provided to guide future research directions.

Keywords: Artificial intelligence, Pharmacokinetics, Pharmacogenomics, Personalized medicine, Machine learning, Deep learning, Next-generation sequencing, Drug response, Precision medicine.

INTRODUCTION

The advent of artificial intelligence (AI) has catalyzed a fundamental shift in how biomedical data is processed, interpreted, and applied to clinical decision-making. Coinciding with this technological revolution is the rapid maturation of pharmacogenomics a discipline that systematically examines how genetic variations influence individual responses to pharmacological agents. Together, AI and pharmacogenomics are converging to form the cornerstone of precision medicine, promising a future in which therapeutic strategies are tailored to the unique biological blueprint of each patient [1,2]. Historically, drug development and prescribing followed a population-averaged paradigm that overlooked substantial inter-individual variability. Adverse drug reactions (ADRs) account for approximately 100,000 deaths annually in the United States alone and constitute a significant global burden on healthcare systems [3]. A substantial proportion of these events are attributable to pharmacogenomic factors particularly polymorphisms in drug-metabolizing enzymes such as cytochrome P450 (CYP) isoforms, drug transporters, and pharmacodynamic targets. Conventional genotyping approaches, while informative, struggle to handle the sheer complexity of multi-gene interactions and their interplay with environmental and clinical variables [4]. Machine learning (ML) and deep learning (DL) algorithms have demonstrated remarkable proficiency in identifying nonlinear patterns within high-dimensional datasets, making them particularly well-suited for genomic applications [5,6]. Natural language processing (NLP) enables the extraction of pharmacogenomic knowledge from unstructured clinical notes and biomedical literature at scale [7]. Reinforcement learning offers pathways toward dynamic, personalized dosing strategies that adapt in real time to patient responses [8]. These capabilities, when applied to the rich genomic and clinical datasets now routinely generated, hold transformative potential for personalized therapeutics [9,10]. This review synthesizes current evidence on AI integration across the pharmacogenomics continuum from drug discovery and preclinical development through clinical application and real-world use and projects a future in which individualized healthcare is enhanced by the synergistic application of AI and precision genomics [11,12].

OVERVIEW OF AI APPLICATIONS IN CLINICAL PHARMACOLOGY

AI applications span the full continuum of clinical pharmacology, from the earliest stages of drug discovery to post-market real-world surveillance. Each phase presents distinct data challenges and opportunities that AI methodologies are increasingly equipped to address [13,14].

Drug (Re)discovery

At the discovery stage, AI algorithms analyze vast chemical libraries to identify lead compounds, elucidate novel drug

targets, and support drug repurposing efforts. Deep learning models trained on molecular fingerprints and bioactivity profiles can accurately predict binding affinity and selectivity, substantially accelerating the hit-to-lead process [13]. Notable examples include AlphaFold's revolutionary contribution to protein structure prediction, which enables structure-based virtual screening at unprecedented scale [15]. AI-driven network pharmacology approaches integrate multi-omics data with drug-target interaction databases to identify repositioning candidates with pharmacogenomic relevance [16].

Preclinical Development

During preclinical development, AI supports the prediction of drug characteristics including absorption, distribution, metabolism, excretion, and toxicity (ADMET). ML models trained on *in vitro* and *in vivo* data can anticipate hepatotoxicity, cardiotoxicity, and off-target effects before resource-intensive animal studies are conducted [17].

AI enhances clinical trial design and conducts through participant selection algorithms that identify genetically eligible subjects, reducing heterogeneity and improving statistical power [19]. Automated follow-up systems powered by NLP monitor patient-reported outcomes and signal emerging safety concerns in real time. Adaptive trial designs informed by interim ML analyses allow dynamic dose modifications and early stopping, improving efficiency and ethical conduct [19].

Real-World Use and Data Mining

Post-approval, AI enables mining of real-world data (RWD) sources including electronic health records (EHRs), insurance claims databases, and patient registries to detect pharmacogenomic signals that were not apparent in controlled trials [20,21]. NLP-driven phenotyping constructs precise genotype-phenotype associations from unstructured clinical narratives, augmenting structured genomic databases [22].

Drug Treatment Optimisation

Pharmacokinetic (PK) modeling using AI integrates individual genomic data with physiological parameters to generate patient-specific PK/PD profiles. Bayesian optimization and reinforcement learning algorithms generate adaptive dosing recommendations that are continuously refined as new therapeutic drug monitoring (TDM) data become available [10]. Pharmacogenomics-based enzyme activity prediction particularly for CYP2D6, CYP2C19, and CYP2C9 is embedded within clinical decision support (CDS) systems to automate individualized prescribing [18,23].

ARTIFICIAL INTELLIGENCE TECHNIQUES IN PHARMACOGENOMICS

A broad spectrum of AI techniques has been applied to pharmacogenomic problems, each with distinct strengths and limitations (Table 1). The selection of an appropriate technique depends on the nature of the data, the prediction task, and the requirements for interpretability and generalizability [6,24].

Machine Learning

Supervised ML algorithms, including random forest, support vector machines (SVM), and gradient boosting, constitute the workhorse of pharmacogenomic prediction. These methods excel in classifying metabolizer phenotypes, predicting ADR risk, and building polygenic risk scores from large genotyped cohorts [25,26]. Unsupervised approaches such as clustering and dimensionality reduction (PCA, UMAP) identify novel genomic subgroups within heterogeneous patient populations [27].

Deep Learning

Convolutional neural networks (CNNs) operate directly on genomic sequence windows to detect motifs predictive of variant functional consequences. Recurrent neural networks (RNNs) and long short-term memory (LSTM) architectures model temporal trajectories of drug exposure and response. Graph neural networks (GNNs) represent molecular structures and protein-protein interaction networks, enabling end-to-end pharmacogenomic modeling [8,28.]

Natural Language Processing

NLP techniques including named entity recognition, relation extraction, and transformer-based models (BERT, BioBERT) curate pharmacogenomic knowledge from the biomedical literature at scale. These methods populate structured pharmacogenomics databases, automate EHR phenotyping, and generate real-time alerts from unstructured clinical reports [22].

Federated and Privacy-Preserving Learning

Federated learning enables AI model training across geographically distributed genomic datasets without centralizing sensitive data, preserving privacy while maximizing sample size diversity. Differential privacy mechanisms add calibrated noise to model parameters, providing formal privacy guarantees. These approaches are particularly important for pharmacogenomics given the sensitive and re-identifiable nature of genomic data [29,30].

MULTI-MODAL DATA INTEGRATION FOR AI-DRIVEN PHARMACOGENOMICS

The realization of AI-driven personalized medicine requires the integration of heterogeneous data streams that collectively characterize the patient's biological state, environmental exposures, and clinical history. Multi-modal data integration frameworks aggregate clinical, laboratory, imaging, omics, wearable device, and environmental information into unified analytical platforms [27,31].

Clinical data encompass demographics, diagnoses, medication histories, and outcome records derived from EHRs. Laboratory data include biochemical assays, therapeutic drug monitoring results, and hematological parameters. Imaging-derived biomarkers quantified by

radiomics and AI-based image analysis provide phenotypic correlates of genomic alterations. Omics data span genomics, transcriptomics, proteomics, and metabolomics, each adding a distinct layer of biological resolution [27]. Wearable devices continuously capture physiological parameters including heart rate, activity, sleep architecture, and glucose levels, enabling dynamic PK/PD surveillance in naturalistic settings [31]. Environmental informatics contextualize genetic expression within the exposome diet, pollutant exposure, socioeconomic factors that modulate drug response independent of genetic determinism. Similarity Network Fusion (SNF) and multi-view learning algorithms synthesize these heterogeneous inputs into coherent patient representations. ML model selection proceeds with awareness of dataset dimensionality, class imbalance, and missingness patterns inherent to multi-modal clinical data. Rigorous model evaluation employs nested cross-validation, external test sets, and calibration assessment to ensure reliable pharmacogenomic predictions [32].

Table 1: Artificial Intelligence Techniques and Their Applications in Pharmacogenomics

AI Technique	Description	Pharmacogenomic Application
Machine Learning (ML)	Algorithms that learn patterns from data without explicit programming.	SNP-drug interaction prediction, adverse drug reaction classification, biomarker discovery.
Deep Learning (DL)	Multi-layered neural networks capable of processing raw genomic sequences.	Variant calling from NGS data, gene expression profiling, protein-drug binding prediction.
Natural Language Processing (NLP)	Extraction of clinically relevant knowledge from unstructured text.	Mining pharmacogenomic associations from literature, EHR phenotyping.
Random Forest	Ensemble decision tree method robust to overfitting.	Classification of CYP450 metabolizer phenotypes, toxicity prediction.
Support Vector Machine (SVM)	Supervised classifier with kernel-based nonlinear decision boundaries.	Gene expression classification, drug response phenotyping.
Convolutional Neural Network (CNN)	Spatial pattern recognition across sequence windows.	Genomic variant effect prediction, splice-site identification.
Recurrent Neural Network (RNN/LSTM)	Sequential data processing with memory retention.	Temporal drug response modeling, longitudinal genomic surveillance.
Reinforcement Learning (RL)	Agent learns optimal actions through reward feedback.	Adaptive dosing regimens, clinical treatment optimization.
Federated Learning	Model training across decentralized datasets without data sharing.	Multi-institutional genomic studies preserving patient privacy.

Table 2: Key Pharmacogenes and AI-Driven Clinical Insights

Gene	Enzyme/Protein	Clinical Relevance	AI Contribution
CYP2D6	Cytochrome P450 2D6	Metabolizes ~25% of drugs; poor/ultra-rapid metabolizers at risk.	ML classification of metabolizer phenotypes from genotype data.
CYP2C19	Cytochrome P450 2C19	Clopidogrel, PPIs, SSRIs metabolism.	Deep learning-based variant effect scoring.
CYP2C9	Cytochrome P450 2C9	Warfarin, NSAIDs, antiepileptics metabolism.	Dosage optimization algorithms integrating clinical covariates.
TPMT	Thiopurine methyltransferase	6-Mercaptopurine toxicity in oncology.	AI-guided dose reduction alerts in oncology EHRs.
DPYD	Dihydropyrimidine dehydrogenase	5-Fluorouracil toxicity risk.	Pretreatment genotype-phenotype ML models.
SLCO1B1	Organic anion transporter	Statin-induced myopathy risk.	Polygenic risk score integration with AI models.
HLA-B*57:01	Human leukocyte antigen	Abacavir hypersensitivity.	NLP extraction from genomic reports for real-time alerts.
UGT1A1	UDP-glucuronosyltransferase	Irinotecan neutropenia risk.	AI-guided dose selection in colorectal cancer protocols.

AI IN PHARMACOGENOMICS: CLINICAL APPLICATIONS

Pharmacogenomics aims to translate genetic information into actionable prescribing decisions. AI amplifies this translation by processing NGS data at scale, deriving gene functionality scores, and integrating pharmacogenomic outputs with therapeutic drug databases to generate individualized clinical guidance [3,33].

NGS Data Analysis and Variant Interpretation

Next-generation sequencing generates millions of genetic variants per individual, the vast majority of clinical significance unknown. AI algorithms trained on curated databases such as PharmGKB, ClinVar, and ClinPharmGKB prioritize variants by predicted functional impact on drug-metabolizing enzymes and pharmacodynamic targets [2,34,35]. Deep learning variant callers (e.g., DeepVariant) outperform traditional bioinformatics pipelines in sensitivity and specificity for single-nucleotide polymorphism (SNP) and indel detection [36].

Gene Functionality Scoring

Diplotype-to-phenotype translation converting detected allele combinations into predicted metabolizer status is a critical step in pharmacogenomic implementation. AI models integrate sequence-level features, population allele frequencies, and in vitro functional data to assign gene functionality scores that encode the predicted enzymatic activity of variant proteins [18,23]. These scores are subsequently interfaced with pharmacological databases to identify drugs whose clearance or efficacy is expected to deviate from population norms in a given patient [37].

Clinical Decision Support Integration

Pharmacogenomic clinical decision support (CDS) systems translate AI-derived gene functionality scores into actionable prescribing alerts within EHR workflows. The CPIC guidelines provide curated gene-drug recommendations that serve as ground truth for CDS logic[18]. AI-enhanced CDS systems extend these static rules by incorporating dynamic patient-level factors comorbidities, comedications, and organ function into individualized dose recommendations [30,38].

Key Pharmacogenes and AI Contributions

Several pharmacogenes have received particular attention in AI-driven research, reflecting their clinical importance and the complexity of their variant-phenotype relationships (Table 2) [18,23,33,39].

AI IN ONCOLOGY PHARMACOGENOMICS

Oncology represents the most advanced domain of pharmacogenomic AI application, driven by the abundance of genomic data from tumor sequencing programs and the urgent therapeutic stakes of cancer treatment. AI models trained on large-scale drug sensitivity screens such as the Cancer Genome Atlas (TCGA) and the Genomics of Drug Sensitivity in Cancer (GDSC) predict tumor cell line responses to hundreds of drugs from genomic profiles [17,40].

Polygenic pharmacogenomic signatures, derived from multi-gene ML models, outperform single-gene biomarkers in predicting chemotherapy toxicity. AI integration of tumor somatic mutations, copy number alterations, and germline pharmacogenomic variants enables comprehensive oncology prescribing guidance. Reinforcement learning-based adaptive dosing algorithms are under investigation for cytotoxic agents where the therapeutic window narrows with cumulative exposure [40,41].

DPYD and UGT1A1 genotyping, aided by AI interpretation of complex variant interactions, is increasingly embedded in oncology EHRs to preemptively identify patients at risk for life-threatening fluoropyrimidine and irinotecan toxicities[39]. Screening automatable via NLP-assisted genomic report parsing prevents abacavir hypersensitivity reactions in HIV management [34].

CHALLENGES AND LIMITATIONS

Despite transformative potential, the integration of AI into pharmacogenomics is confronted by substantial scientific, ethical, and practical barriers that must be systematically addressed before widespread clinical implementation[29,39,42].

Data Quality and Population Diversity

The quality of AI predictions is fundamentally constrained by the quality and representativeness of training data. Current genomic databases are predominantly derived from individuals of European ancestry, creating models with reduced accuracy for non-European populations [43]. Efforts such as the H3 Africa Consortium and the All of Us Research Program are expanding population diversity in pharmacogenomic databases, but substantial gaps persist[44].

Interpretability and Clinical Trust

The opacity of deep learning models limits clinician trust and regulatory acceptance. Explainable AI (XAI) methods including SHAP (SHapley Additive exPlanations), LIME (Local Interpretable Model-agnostic Explanations), and attention visualization provide post-hoc explanations of model decisions. However, the fidelity of these explanations to true model mechanisms remains an area of active investigation [45].

Regulatory and Ethical Framework

No established regulatory pathway exists for AI-driven pharmacogenomic clinical decision tools in most jurisdictions. The FDA and EMA have published guidance documents on AI/ML-based software as a medical device (SaMD), but genomic-specific validation requirements remain nascent [34,35]. Ethical concerns encompass data ownership, informed consent for secondary genomic data use, algorithmic bias, and the equitable distribution of pharmacogenomic AI benefits [29,42].

FUTURE OUTLOOK

The future of AI in pharmacogenomics is inextricably linked to the broader vision of individualized healthcare that

addresses clinical, social, and genomic dimensions of therapeutic decision-making [46,47].

AI and Precision Medicine Convergence

The synthesis of AI with precision medicine frameworks will increasingly encompass polygenic risk stratification, pharmacomicrobiome interactions, and epigenomic modifiers of drug response. Foundation models large-scale transformer architectures pretrained on diverse biomedical corpora will serve as versatile platforms for pharmacogenomic knowledge generation, requiring only fine-tuning on task-specific datasets [48].

Clinical Considerations

Clinical implementation of AI pharmacogenomics requires seamless EHR integration, clinician education, and reimbursement policies that incentivize preemptive genotyping. The pharmacist's role is evolving toward genomic medication management, with AI CDS tools supporting pharmacogenomics-based medication reviews at the point of prescribing [30,38]. Randomized controlled trials evaluating pharmacogenomics-guided prescribing such as the PREPARE trial are providing level-1 evidence for clinical benefit [33].

Table 3: Challenges in AI-Pharmacogenomics Integration and Proposed Solutions

Challenge	Description	Proposed Solution
Data Heterogeneity	Genomic, clinical, and imaging data differ vastly in format and scale.	Standardized ontologies (HL7 FHIR, SNOMED CT), multi-modal fusion architectures.
Algorithmic Bias	Training data underrepresentation of non-European ancestry populations.	Diverse population cohorts; fairness-aware ML training.
Interpretability	Black-box models limit clinical trust.	Explainable AI (XAI) techniques: SHAP, LIME, attention mechanisms.
Data Privacy	Genomic data is irreversibly identifiable.	Federated learning, differential privacy, secure multi-party computation.
Regulatory Uncertainty	No established pathways for AI-genomic clinical decision tools.	Engagement with FDA, EMA; development of AI-specific validation frameworks.
Clinical Integration	Fragmented EHR systems hinder AI deployment.	Interoperable APIs, pharmacogenomics clinical decision support (CDS) hooks.
Reproducibility	Models trained on one population may not generalize.	External validation, multi-center studies, model cards and reporting standards.

Social and Equity Considerations

Equitable access to AI-pharmacogenomics requires deliberate strategies to prevent the exacerbation of health disparities. Community engagement in genomic research, culturally tailored consent processes, and population-inclusive model development are essential. Social determinants of health must be incorporated into AI models as contextual covariates alongside genomic predictors to yield equitable precision prescribing [42,43].

Genomic Considerations

Advances in long-read sequencing, single-cell genomics, and spatial transcriptomics will generate richer pharmacogenomic phenotypes for AI modeling. Pharmacoepigenomics the study of heritable epigenetic marks that modulate drug response represents an emerging frontier where AI methods are beginning to yield insights beyond static genomic variants [24,27]. Integration of somatic mosaicism, structural variants, and non-coding regulatory regions into pharmacogenomic AI models will substantially expand the predictive landscape [36].

CONCLUSION

The integration of artificial intelligence into pharmacogenomics represents one of the most promising developments in contemporary biomedical science. By harnessing the pattern-recognition capabilities of ML and DL algorithms, the knowledge extraction power of NLP, and the adaptive optimization of reinforcement learning, AI is transforming pharmacogenomics from a largely correlative discipline into a dynamic clinical tool capable of real-time, individualized therapeutic guidance. Multi-modal data integration frameworks that consolidate clinical, genomic, environmental, and wearable-derived information are essential enablers of this transformation. The pharmacogenomic workflow from NGS data generation through gene functionality scoring to clinical prescribing guidance is increasingly automated and AI-augmented, reducing the time from genomic discovery to bedside application. Substantial challenges remain, particularly in population diversity, model interpretability, regulatory validation, and ethical implementation. Addressing these challenges requires coordinated action from clinicians, data scientists, regulators, and patient advocates. The future outlook envisions a healthcare ecosystem wherein AI and precision medicine synergistically enhance individualized

therapeutic decision-making across clinical, social, and genomic dimensions realizing the long-held promise of the right drug, at the right dose, for the right patient, at the right time.

Source of Support: The author(s) received no financial support for the research, authorship, and/or publication of this article

Conflict of Interest: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

1. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343-350.
2. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417.
3. Weinshilboum RM, Wang L. Pharmacogenomics: precision medicine and drug response. Mayo Clin Proc. 2017;92(11):1711-1722.
4. Obermeyer Z, Emanuel EJ. Predicting the future — big data, machine learning, and clinical medicine. N Engl J Med. 2016;375(13):1216-1219.
5. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
6. Chicco D. Ten quick tips for machine learning in computational biology. BioData Min. 2017;10(1):35.
7. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436-444.
8. Eraslan G, Avsec Ž, Gagneur J, Theis FJ. Deep learning: new computational modelling techniques for genomics. Nat Rev Genet. 2019;20(7):389-403.
9. Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A. Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. Mol Pharm. 2016;13(7):2524-2530.
10. Gottesman O, Johansson F, Komorowski M, Faisal AA, Sontag D, Doshi-Velez F, Celi LA. Guidelines for reinforcement learning in healthcare. Nat Med. 2019;25(1):16-18.
11. Miotto R, Wang F, Wang S, Jiang X, Dudley JT. Deep learning for healthcare: review, opportunities and challenges. Brief Bioinform. 2018;19(6):1236-1246.
12. Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, Wang Y, Dong Q, Shen H, Wang Y. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230-243.
13. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-477.
14. Stegemann S, Borner K. Machine learning and pharmacogenomics: a systematic review. J Pharm Sci. 2021;110(7):2732-2741.
15. Denny JC, Collins FS. Precision medicine in 2030—seven ways to transform healthcare. Cell. 2021;184(6):1415-1419.
16. Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff (Millwood). 2018;37(5):694-701.
17. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RHN, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VHM, Guchelaar HJ. Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.
18. Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012;22(2):159-165.
19. Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Davila-Fajardo CL, Deneer VHM, Dolzan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Klein TE, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl JC, Swen JJ, Tasa G, van der Straaten T, van Schaik RHN, van der Weide J, Vermeulen SH, Wilffert B, Guchelaar HJ. A 12-gene pharmacogenomic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347-356.
20. Naidoo P, Chetty M, Bhagwandhin S. Pharmacogenomics and personalized medicine: a review of clinical applications. J Appl Genet. 2018;59(4):375-384.
21. van der Lee M, Allard WG, Bollen S, Santen GWE, van Schaik RHN, van Gelder T, Swen JJ, Guchelaar HJ. Multigene pharmacogenomic testing for predicting antidepressant response. Pharmacogenomics. 2020;21(13):903-917.
22. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, Bridgland A, Meyer C, Kohl SAA, Ballard AJ, Cowie A, Romera-Paredes B, Nikolov S, Jain R, Adler J, Back T, Petersen S, Reiman D, Clancy E, Zielinski M, Steinegger M, Pacholska M, Berghammer T, Bodenstein S, Silver D, Vinyals O, Senior AW, Kavukcuoglu K, Kohli P, Hassabis D. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-589.
23. Chen IY, Agrawal M, Horng S, Sontag D. Robustly extracting medical knowledge from EHRs: a case study of learning a health knowledge graph. Pac Symp Biocomput. 2020;25:19-30.
24. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med. 2022;28(1):31-38.
25. Buza K, Nanopoulos A, Schmidt-Thieme L. INSIGHT: efficient and effective instance selection for time-series classification. Lect Notes Comput Sci. 2011;7104:137-151.
26. Huang BF, Boutros PC. The parameter sensitivity of random forests. BMC Bioinformatics. 2016;17(1):331.
27. Menden MP, Iorio F, Garnett M, McDermott U, Benes CH, Ballester PJ, Saez-Rodriguez J. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One. 2013;8(4):e61318.
28. Adam G, Rampášek L, Safikhani Z, Smirnov P, Haibe-Kains B, Goldenberg A. Machine learning approaches to drug response prediction: challenges and recent progress. NPJ Precis Oncol. 2020;4(1):19.

29. Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, Curigliano G. Complexity of genome sequencing and reporting: next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol. 2019;133:171-182.
30. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538(7624):161-164.
31. Char DS, Shah NH, Magnus D. Implementing machine learning in health care addressing ethical challenges. N Engl J Med. 2018;378(11):981-983.
32. Price WN, Cohen IG. Privacy in the age of medical big data. Nat Med. 2019;25(1):37-43.
33. Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, Van Driest SL. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2019;171(5):347-356.
34. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793-795.
35. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4-23.
36. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
37. Huo MN, Bhatt DL, Bhatt NS. Machine learning for cardiovascular risk prediction: a systematic review. Am J Cardiol. 2021;158:90-98.
38. Lotfi Shahreza M, Ghadiri N, Mousavi SR, Varshosaz J, Green JR. A review of network-based approaches to drug repositioning. Brief Bioinform. 2018;19(5):878-892.
39. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-D1082.
40. Ritchie MD, Holzinger ER, Li R, Pendergrass SA, Kim D. Methods of integrating data to uncover genotype-phenotype interactions. Nat Rev Genet. 2015;16(2):85-97.
41. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65-74.
42. Shortliffe EH, Sepúlveda MJ. Clinical decision support in the era of artificial intelligence. JAMA. 2018;320(21):2199-2200.
43. Berger SI, Bhatt DL. Polygenic risk score — from research to clinical practice. JAMA Cardiol. 2021;6(11):1239-1240.
44. Sridhar GR. Artificial intelligence in the study of diabetic complications. World J Diabetes. 2020;11(4):114-121.
45. Huang K, Fu T, Gao W, Xiao C, Glass LM, Sun J. Therapeutics data commons: machine learning datasets and tasks for drug discovery and development. Adv Neural Inf Process Syst. 2021;34:24625-24638.
46. Komorowski M, Celi LA, Badawi O, Gordon AC, Faisal AA. The artificial intelligence clinician learns optimal treatment strategies for sepsis in intensive care. Nat Med. 2018;24(11):1716-1720.
47. Shu C, Huang HC. Advances in wearable sensors for monitoring physiological signals and its application in clinical pharmacology. Curr Pharm Des. 2020;26(25):3019-3030.
48. Wang B, Mezlini AM, Demir F, Fiume M, Tu Z, Brudno M, Haibe-Kains B. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods. 2014;11(3):333-337.
49. Tonekaboni S, Joshi S, McCradden MD, Goldenberg A. What clinicians want: contextualizing explainable machine learning for clinical end use. Mach Learn Healthc. 2019;106:359-380.
50. Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. Nat Rev Genet. 2015;16(6):321-332.
51. Zong N, Wen A, Stone DJ, Hart SN, Kipp BR, Klee EW, Chute CG. Democratizing EHR analyses with RDAMA: an open-source pharmacogenomic knowledge base application programming interface integrated with clinical data. J Am Med Inform Assoc. 2021;28(6):1379-1387.
52. Azencott CA. Machine learning and genomics: precision medicine versus patient privacy. Philos Trans R Soc A Math Phys Eng Sci. 2018;376(2128):20170350.
53. Weng SF, Reps J, Kai J, Garibaldi JM, Qureshi N. Can machine-learning improve cardiovascular risk prediction using routine clinical data? PLoS One. 2017;12(4):e0174944.
54. Khozin S, Blumenthal GM, Pazdur R. Real-world data for clinical evidence generation in oncology. J Natl Cancer Inst. 2017;109(11):djx187.
55. Abràmoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ Digit Med. 2018;1(1):39.
56. Ekins S, Puhl AC, Zorn KM, Lane TR, Russo DP, Klein JJ, Hickey AJ, Clark AM. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019;18(5):435-441.